Finance

Angina-focused company reports strong Q4 and 2004 results

Published in Medical Letter on the CDC and FDA, February 27th, 2005

CardioGenesis Corp. (CGCP), a company focused on surgical products and accessories used in angina-relieving transmyocardial revascularization (TMR) and percutaneous myocardial channeling procedures, announced that fourth quarter and 2004 annual revenues are expected to be at their highest level in the last 4 years.

Strong TMR handpiece sales combined with laser sales in the fourth quarter resulted in expected revenues in the range of $4.9-5.1 million for the fourth quarter and $15.2-15.4 million for the year. These results reflect an estimated 80% quarter-to-quarter increase in revenues from the 2004 third quarter, a 48% increase in revenues compared to Q4 of 2003, and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-02-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry